Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Oncol Rep ; 17(2): 433-9, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17203184

ABSTRACT

1-O-octadecyl-2-O-methylglycero-3-phosphocholine (ET-18-OMe)-treated precultured heart fragments (PHF) are resistant to the invasion of malignant cells. Previous studies have demonstrated that this effect is due to the alterations of the N-linked glycoproteins in PHF after 48-h ET-18-OMe treatment. Moreover, the observed effect was still present seven days after ET-18-OMe was omitted. The present study reveals that approximately 13.4% of the administered ET-18-OMe was taken up by PHF and about 75% of the initial uptake was still present after ET-18-OMe was removed. In addition, we found significant changes in the sialic acid content and sialyltransferase activities in both conditions. Overall, these results clearly demonstrate that the uptake and retention of ET-18-OMe are responsible for the resistance to the invasion of malignant cells due to the altered sialylation of the cell surface glycoproteins in PHF.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Screening Assays, Antitumor/methods , Myocardium/pathology , Phospholipid Ethers/pharmacology , Sialic Acids/metabolism , Animals , Biotinylation , Blotting, Western , Cell Membrane/metabolism , Chick Embryo , Glycoproteins/metabolism , Models, Chemical , N-Acetylneuraminic Acid/metabolism , Neoplasm Invasiveness , Sialyltransferases/metabolism
2.
Int J Biol Markers ; 18(2): 116-22, 2003.
Article in English | MEDLINE | ID: mdl-12841680

ABSTRACT

AIMS AND BACKGROUND: A crucial step in the metastatic process is the interaction between the endothelial molecule E-selectin and its tumoral ligands sialyl-Lewis- and sialyl-Lewis. Sialyltranferases are involved in the biosynthesis of these ligands. The aim of this study was to assess the prognostic value of tumoral sialyltransferase expression and of circulating soluble E-selectin (sE-selectin) in node-negative breast cancer patients. METHODS: Using a multiplex RT-PCR method, we measured the expression of five sialyltransferases (ST3Gal III, ST6Gal I, ST3Gal IV, ST3Gal I and ST3Gal II) in tumors of 135 surgically treated node-negative breast cancer patients. Circulating sE-selectin concentrations were measured by an ELISA method prior to surgery. We also analyzed tumor size, histoprognostic grading and steroid hormone receptor status. RESULTS: The median follow-up was 7.5 years. Expression of estrogen receptors was associated with a good prognosis for relapse-free survival in univariate analysis. A high ST3Gal III/ST6Gal I ratio and a high sE-selectin concentration were associated with a bad prognosis for relapse-free survival and overall survival in univariate and multivariate analysis. CONCLUSION: In the present study, tumoral sialyltransferase expression and circulating sE-selectin concentrations had prognostic value in patients with node-negative breast cancer. This result provides further evidence for the important role of these agents in the metastatic process.


Subject(s)
Breast Neoplasms/mortality , E-Selectin/blood , Sialyltransferases/analysis , Adult , Aged , Aged, 80 and over , Breast Neoplasms/blood , Breast Neoplasms/enzymology , Female , Humans , Lymphatic Metastasis , Middle Aged , Prognosis , Survival Rate
3.
Biochimie ; 83(8): 727-37, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11530204

ABSTRACT

The human genome encodes probably more than 20 different sialyltransferases involved in the biosynthesis of sialylated glycoproteins and glycolipids but to date only 15 different human sialyltransferase cDNAs have been cloned and characterized. Each of the sialyltransferase genes is differentially expressed in a tissue-, cell type-, and stage-specific manner to regulate the sialylation pattern of cells. These enzymes differ in their substrate specificity, tissue distribution and various biochemical parameters. However, enzymatic analysis conducted in vitro with recombinant enzyme revealed that one linkage can be synthesized by multiple enzymes. We present here an overview of these human genes and enzymes, the regulation of their occurrence and their involvement in several physiological and pathological processes.


Subject(s)
Sialyltransferases/genetics , Amino Acid Sequence , Animals , Cloning, Molecular , Gene Expression Regulation, Enzymologic , Humans , Mammals , Molecular Sequence Data , Protein Conformation , Sialyltransferases/chemistry , Sialyltransferases/metabolism , Substrate Specificity
4.
J Cell Sci ; 114(Pt 8): 1455-71, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11282022

ABSTRACT

Our previous work has shown that long-term treatment of mucus-secreting HT-29 cells with 1-benzyl-2-acetamido-2-deoxy-alpha-D-galactopyranoside (GalNAcalpha-O-bn), a competitive inhibitor of O-glycosylation, induced several phenotypic changes, in particular a blockade in the secretion of mucins, which are extensively O-glycosylated glycoproteins. Here, we have analyzed the effects of GalNAcalpha-O-bn upon the intracellular trafficking of basolateral and apical membrane glycoproteins at the cellular and biochemical levels in two types of cells, HT-29 G(-) and Caco-2, differentiated into an enterocyte-like phenotype. In HT-29 G(-) cells, but not in Caco-2 cells, DPP-IV and CD44 failed to be targeted to the apical or basolateral membrane, respectively, and accumulated inside intracytoplasmic vesicles together with GalNAcalpha-O-bn metabolites. We observed a strong inhibition of alpha2,3-sialylation of glycoproteins in HT-29 G(-) cells correlated to the high expression of alpha2,3-sialyltransferases ST3Gal I and ST3Gal IV. In these cells, DPP-IV and CD44 lost the sialic acid residue substituting the O-linked core 1 structure Galbeta1-3GalNAc (T-antigen). In contrast, sialylation was not modified in Caco-2 cells, but a decrease of alpha1,2-fucosylation was observed, in correlation with the high expression of alpha1,2-fucosyltransferases Fuc-TI and Fuc-TII. In conclusion, in HT-29 G(-) cells, GalNAcalpha-O-bn induces a specific cellular phenotype, which is morphologically characterized by the formation of numerous intracellular vesicles, in which are accumulated defectively sialylated O-glycosylproteins originally targeted to basolateral or apical membranes, and GalNAcalpha-O-bn metabolites.


Subject(s)
Fucosyltransferases/genetics , Galactose/analogs & derivatives , Galactose/administration & dosage , Galactose/metabolism , Glycosylation/drug effects , Protein Transport/physiology , Sialyltransferases/genetics , Caco-2 Cells/metabolism , Cell Differentiation , Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/drug effects , Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/metabolism , Enzyme Activation/physiology , Epitopes/immunology , Epitopes/metabolism , Fucosyltransferases/metabolism , Gene Expression/genetics , HT29 Cells/metabolism , Humans , Hyaluronan Receptors/drug effects , Hyaluronan Receptors/metabolism , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/drug effects , Membrane Glycoproteins/metabolism , Monosaccharides/chemistry , Monosaccharides/metabolism , Polysaccharides/immunology , Polysaccharides/metabolism , Protein Transport/drug effects , Sialyltransferases/metabolism , Tumor Cells, Cultured
5.
Int J Cancer ; 92(4): 527-36, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11304687

ABSTRACT

1-O-octadecyl-2-O-methyl-glycerophosphocholine (ET-18-OMe) is an analogue of the naturally occurring 2-lysophosphatidylcholine belonging to the class of antitumor lipids. Previously, we demonstrated that ET-18-OMe modulates cell-cell adhesion of human breast cancer MCF-7 cells. In the present study, we tested the effect of ET-18-OMe on adhesion, invasion and localisation of episialin and E-cadherin in MCF-7/AZ cells expressing a functional E-cadherin/catenin complex. The MCF-7/6 human breast cancer cells were used as negative control since their E-cadherin/catenin complex is functional in cells grown on solid substrate but not in suspension. The function of E-cadherin, a calcium-dependent transmembrane cell-cell adhesion and signal-transducing molecule, is disturbed in invasive cancers by mutation, loss of mRNA stability, proteolytic degradation, tyrosine phosphorylation of associated proteins and large cell-associated proteoglycans or mucin-like molecules such as episialin. Episialin, also called MUC1, is an anti-adhesion molecule that by its large number of glycosylated tandem repeats can sterically hinder the adhesive properties of other glycoproteins. ET-18-OMe inhibited the E-cadherin functions of MCF-7/AZ cells as measured by inhibition of fast and slow aggregation and by the induction of collagen invasion. These effects were enhanced by MB2, an antibody against E-cadherin and blocked by monoclonal antibodies (MAbs) 214D4 or M8 against episialin. ET-18-OMe had no influence on tyrosine phosphorylation of beta-catenin and the E-cadherin/catenin complex remained intact. Transcription, translation, protein turnover and cell surface localisation of episialin were not altered. ET-18-OMe induced finger-like extensions with clustering of episialin together with E-cadherin and carcinoembryonic antigen but not with occludin. In cells in suspension, ET-18-OMe caused a shift in the flow-cytometric profile of episialin toward a lower intensity for MCF-7/AZ cells. In contrast with MCF-7/AZ cells, the adhesion-deficient and noninvasive MCF-7/6 cells showed neither morphotypic changes nor induction of aggregation nor invasion in collagen I upon treatment with ET-18-OMe. Co-localisation of episialin with E-cadherin was rarely observed. We conclude that in the human breast cancer cells MCF-7/AZ, E-cadherin and episialin are key molecular players in the regulation of promotion and suppression of cell-cell adhesion and invasion.


Subject(s)
Breast Neoplasms/pathology , Cadherins/metabolism , Enzyme Inhibitors/pharmacology , Mucin-1/pharmacology , Phosphatidylcholines/pharmacology , Trans-Activators , Antibodies, Monoclonal/metabolism , Biotinylation , Blotting, Northern , Blotting, Western , Cell Adhesion , Cell Aggregation , Cell Membrane/metabolism , Cell Survival , Collagen/metabolism , Cytoskeletal Proteins/metabolism , Flow Cytometry , Humans , Immunoblotting , Microscopy, Confocal , Microscopy, Fluorescence , Mucin-1/biosynthesis , Mucin-1/metabolism , Neoplasm Invasiveness , Phenotype , Phospholipid Ethers , Phosphorylation , Precipitin Tests , Protein Binding , Radioimmunoassay , Signal Transduction , Time Factors , Tumor Cells, Cultured , Tyrosine/metabolism , beta Catenin
6.
Glycoconj J ; 18(11-12): 883-93, 2001.
Article in English | MEDLINE | ID: mdl-12820722

ABSTRACT

Sialyl-Tn antigen (STn) is a cancer associated carbohydrate antigen over-expressed in several cancers including breast cancer, and currently associated with more aggressive diseases and poor prognosis. However, the commonly used breast cancer cell lines (MDA-MB-231, T47-D and MCF7) do not express STn antigen. The key step in the biosynthesis of STn is the transfer of a sialic acid residue in alpha2,6-linkage to GalNAc alpha-O-Ser/Thr. This reaction is mainly catalyzed by a CMP-Neu5Ac GalNAc alpha2,6-sialyltransferase: ST6GalNAc I. In order to generate STn-positive breast cancer cells, we have cloned a cDNA encoding the full-length human ST6GalNAc I from HT-29-MTX cells. The stable transfection of MDA-MB-231 with an expression vector encoding ST6GalNAc I induces the expression of STn antigen at the cell surface. The expression of STn short cuts the initial O-glycosylation pattern of these cell lines, by competing with the Core-1 beta1,3-galactosyltransferase, the first enzyme involved in the elongation of O-glycan chains. Moreover, we show that STn expression is associated with morphological changes, decreased growth and increased migration of MDA-MB-231 cells.


Subject(s)
Antigens, Tumor-Associated, Carbohydrate/metabolism , Breast Neoplasms/immunology , Breast Neoplasms/metabolism , Sialyltransferases/genetics , Antigens, Tumor-Associated, Carbohydrate/chemistry , Biomarkers, Tumor , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Carbohydrate Conformation , Carbohydrate Sequence , Cell Membrane/immunology , Cell Membrane/metabolism , Cell Movement , Cloning, Molecular , Colonic Neoplasms/enzymology , Colonic Neoplasms/genetics , DNA, Complementary/genetics , Female , Galactosyltransferases/metabolism , Glycosylation , Humans , Molecular Sequence Data , Reverse Transcriptase Polymerase Chain Reaction , Sialyltransferases/metabolism , Transfection , Tumor Cells, Cultured
7.
Biochem J ; 352 Pt 1: 37-48, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11062056

ABSTRACT

On the basis of the detection of expressed sequence tag ('EST') similar to the rat N-acetylgalactosamine alpha2,6-sialyltransferase (ST6GalNAc) III cDNA, we have identified a novel member of the human ST6GalNAc family. We have isolated a cDNA clone containing an open reading frame that codes for a type II membrane protein of 302 amino acids with a seven-amino-acid cytoplasmic domain, an 18-amino-acid transmembrane domain and the smallest described catalytic domain of 277 amino acids. This predicted sialyltransferase sequence is similar to the rat ST6GalNAc III (46.6%), but was found to be even more similar to the recently reported mouse ST6GalNAc IV (88.1%) on the basis of amino acid sequence identity. Northern-blot analysis showed that the newly identified gene is expressed constitutively in various adult human tissues as a 2.2kb transcript, but was also found to be expressed at lower levels in brain, heart and skeletal muscle as a 2.5kb transcript. Expression of the hST6GalNAc IV gene was investigated by reverse transcription PCR in various human cancer cells, and was found to be present in the majority of cell types with the exception of the carcinoma cell line T47D and pro-monocyte THP cells. The transient expression in COS-7 cells of the full-length cDNA led to the production of an active enzyme sharing the acceptor specificity of the ST6GalNAc family towards Neu5Ac alpha 2-3Gal beta 1-3GalNAc alpha-O-R (where 'R' denotes H, benzyl, or a peptidic chain). Detailed analysis in vitro of substrate specificity revealed that the enzyme required the trisaccharide Neu5Ac alpha 2-3Gal beta1-3GalNAc found on O-glycans and arylglycosides. In addition, we have clarified the genomic organization of ST6GalNAc IV gene.


Subject(s)
Sialyltransferases/biosynthesis , Sialyltransferases/genetics , Amino Acid Sequence , Animals , Base Sequence , Blotting, Northern , Blotting, Western , COS Cells , Catalytic Domain , Chromosomes, Human, Pair 9 , Cloning, Molecular , Cytoplasm/metabolism , DNA, Complementary/metabolism , Expressed Sequence Tags , Fluorescent Antibody Technique , Humans , Kinetics , Mice , Microscopy, Fluorescence , Models, Genetic , Molecular Sequence Data , Open Reading Frames , Protein Structure, Tertiary , RNA/metabolism , Rats , Recombinant Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Amino Acid , Sialyltransferases/metabolism , Substrate Specificity , Tissue Distribution , Transfection , Tumor Cells, Cultured
8.
Biochim Biophys Acta ; 1474(2): 201-11, 2000 Apr 06.
Article in English | MEDLINE | ID: mdl-10742600

ABSTRACT

A cDNA clone encoding a human Galbeta1-3GalNAc alpha2, 6-sialyltransferase (designated hST6GalNAc II) was identified employing the PCR with degenerated primers to the sialylmotifs, followed by BLAST analysis of databanks. This sialyltransferase sequence is similar to that of previously cloned ST6GalNAc II (chicken and mouse) and shows the sialylmotifs that are present in all eukaryotic members of the sialyltransferase gene family. The predicted amino acid sequence encodes a putative type II transmembrane protein as found for other eukaryotic sialyltransferases and shows significant similarity to chicken (56. 8% identity) and mouse (74.6% identity) enzymes. Expression of a secreted form of hST6GalNAc II in COS-7 cells showed that the gene product had Galbeta1-3GalNAc (sialyl to GalNAc) alpha2, 6-sialyltransferase activity. In vitro analysis of substrate specificity revealed that the enzyme required a peptide aglycone fraction to be active and used both Galbeta1-3GalNAc and Neu5Acalpha2-3Galbeta1-3GalNAc as acceptor substrates. Northern analysis revealed a restricted expression pattern of two hST6GalNAc II transcripts, a 2.0 kb mRNA found mainly in skeletal muscle, heart and kidney and a 1.8 kb mRNA found in placenta, lung and leukocytes. No transcriptional expression was detected in brain, thymus or spleen. Transcriptional expression of the ST6GalNAc II gene was followed in various human cell lines and found to be expressed in almost all cell types with notable exceptions for several myeloid and lymphoid cell lines.


Subject(s)
Sialyltransferases/genetics , Amino Acid Sequence , Animals , Base Sequence , Carbohydrate Sequence , Cell Line , Cloning, Molecular , DNA, Complementary , Humans , Kinetics , Molecular Sequence Data , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sialyltransferases/metabolism , Substrate Specificity , Tumor Cells, Cultured
9.
Mol Cell Biol Res Commun ; 3(1): 48-52, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10683317

ABSTRACT

We have addressed the effects of estradiol and 4-OH-tamoxifen on the expression of five sialyltransferases in the hormono-dependent MCF-7 cell line using a Multiplex RT-PCR approach. Estradiol induced a statistically significant increase in ST3Gal III and a decrease in ST6Gal I, whereas the two other enzymes, ST3Gal IV and ST3Gal I, are not modified and expression of the fifth enzyme, ST3Gal II, was very low or not detectable. Estradiol effects were dose dependent and completely antagonized by 4OH-tamoxifen. In addition, there is no direct relation between cellular proliferation and sialyltransferase expression. This suggests that ST3Gal III and ST6Gal I could be used as supplementary markers of hormono-sensitivity in breast cancer.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms/enzymology , Estradiol/pharmacology , Gene Expression Regulation, Enzymologic , Sialyltransferases/genetics , Sialyltransferases/metabolism , Tamoxifen/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Dose-Response Relationship, Drug , Gene Expression Regulation, Enzymologic/drug effects , Humans , RNA/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured , beta-Galactoside alpha-2,3-Sialyltransferase
10.
Clin Exp Metastasis ; 17(3): 245-53, 1999 May.
Article in English | MEDLINE | ID: mdl-10432010

ABSTRACT

We have investigated the role of sialylation on cell-cell adhesion mediated by E-cadherin. Two MCF-7 human breast cancer cell variants were studied: MCF-7/AZ cells showed a spontaneous cell-cell adhesion in the fast and slow aggregation assay. whereas the adhesion deficient MCF-7/6 cell variant failed to form larger aggregates, suggesting that E-cadherin was not functional under the conditions of both assays. We measured the sialyltransferase activities using Galbeta1-3GalNAcalpha-O-benzyl and Galbeta1-4GlcNAcalpha-O-benzyl as acceptor substrates as well as mRNA levels of four sialyltransferases, ST3Gal I, ST3Gal III, ST3Gal IV, ST6Gal I, using multiplex RT-PCR in MCF-7 cell variants. The alpha2-6 and alpha2-3 sialylation of E-cadherin was investigated by immuno-blot using Sambucus nigra agglutinin and Maackia amurensis agglutinin. Compared to the adhesion-proficient MCF-7/AZ cells, the adhesion-deficient MCF-7/6 cell line apparently lacks ST6Gal I mRNA, has a lower ST3Gal I mRNA, a lower ST3Gal I sialyltransferase activity, and no alpha2-3 linked sialic acid moieties on E-cadherin. The potential anti-cancer drug 1-O-octadecyl-2-O-methylglycero-3-phosphocholine (ET-18-OMe, 48 h, 25 microg/ml) belonging to the class of alkyllysophospholipids restored the E-cadherin function in the adhesion-deficient MCF-7/6 cells as evidenced by an increased aggregation. ET-18-OMe caused loss of ST6Gal I mRNA in MCF-7/AZ cells but no changes of sialyltransferase activities or sialic acid moieties on E-cadherin could be observed. We conclude that Ca2+-dependent, E-cadherin-specific homotypic adhesion of MCF-7/AZ or MCF-7/6 cells treated with ET-18-OMe was not affected by sialylation of E-cadherin.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/pathology , Cadherins/metabolism , Phosphodiesterase Inhibitors/pharmacology , Phospholipid Ethers/pharmacology , Sialic Acids/metabolism , Breast Neoplasms/enzymology , Breast Neoplasms/metabolism , Cell Aggregation/drug effects , Cell Survival/drug effects , Female , Glycoproteins/metabolism , Humans , Immunoblotting , Precipitin Tests , Reverse Transcriptase Polymerase Chain Reaction , Sialyltransferases/biosynthesis , Sialyltransferases/metabolism , Tumor Cells, Cultured
11.
Cancer Res ; 58(18): 4066-70, 1998 Sep 15.
Article in English | MEDLINE | ID: mdl-9751611

ABSTRACT

Increased sialylation, especially involving the Sialyl-Lewisa and Sialyl-Lewisx determinants, has been reported in breast cancer. A multiplex reverse transcription-PCR method was used here to determine the expression of five sialyltransferases (ST3Gal III, ST6Gal I, ST3Gal IV, ST3Gal I, and ST3Gal II) in 49 patients surgically treated for locoregional breast cancer. We assessed the relationship between these expressions and clinical, pathological, and biological features. The most expressed sialyltransferase was ST3Gal 1II, which is involved in Sialyl-Lewisa synthesis. ST3Gal III expression was positively correlated to ST6Gal I and ST3Gal IV expressions, to tumor size, and to the number of involved axillary nodes. Patients with high ST3Gal III expression had a shorter overall survival. High ST6Gal I expression was associated with histoprognostic grade III. ST6Gal I expression was negatively correlated to expression of progesterone receptor. In conclusion, high ST3Gal III and ST6Gal I expressions in human breast tumors are associated with poor prognosis markers.


Subject(s)
Breast Neoplasms/metabolism , Neoplasm Proteins/metabolism , Sialyltransferases/metabolism , Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Polymerase Chain Reaction/methods , Retrospective Studies , Sialyltransferases/analysis , Survival Analysis , beta-D-Galactoside alpha 2-6-Sialyltransferase , beta-Galactoside alpha-2,3-Sialyltransferase
12.
Biochem J ; 334 ( Pt 1): 283-95, 1998 Aug 15.
Article in English | MEDLINE | ID: mdl-9693131

ABSTRACT

Previous work has shown that treatment of HT-29 methotrexate (MTX) cells with benzyl-N-acetyl-alpha-D-galactosaminide results in profound changes in mucin oligosaccharide chains. To analyse in depth the effect of this drug, we first determined the structure of mucin oligosaccharide chains synthesized by HT-29 MTX cells and the changes induced by permanent drug exposure. Mucins from untreated cells contained nine monosialylated structures (core types 1, 2, 3 and 4) and four disialylated structures (types 1, 2 and 4). Core 1 structures predominated, in particular NeuAcalpha2-3Galbeta1-3GalNAc-ol. Exposure of HT-29 MTX cells to benzyl-N-acetyl-alpha-D-galactosaminide from days 2-21 resulted in a decrease in intracellular mucins and both their sialic acid and galactose content, and an increased T (Galbeta1-3GalNAcalpha-O-Ser/Thr) and Tn (GalNAcalpha-O-Ser/Thr) antigenicity. A 3-fold increase in both Galbeta1-3GalNAc alpha2, 3-sialyltransferase activity and mRNA expression was detected. At the ultrastructural level, T-antigen was not detectable in mucin droplets in control cells, but was strongly expressed in intracytoplasmic vesicles in treated cells. In these cells, MUC1 and MUC3 transcripts were up-regulated, whereas MUC2, MUC5B and MUC5AC were down-regulated. Furthermore, constitutive and secretagogue-induced MUC5AC secretion was reduced and no mucus layer was detected. In conclusion, benzyl-N-acetyl-alpha-D-galactosaminide induces abnormal O-glycosylation and altered regulation of MUC5AC secretion.


Subject(s)
Acetylgalactosamine/analogs & derivatives , Benzyl Compounds/pharmacology , Mucins/biosynthesis , Mucins/metabolism , Oligosaccharides/biosynthesis , Acetylgalactosamine/pharmacology , Adenocarcinoma , Carbohydrate Sequence , Colonic Neoplasms , Galactose/metabolism , Glycosylation , Glycosyltransferases/metabolism , Humans , Kinetics , Microsomes/enzymology , Molecular Sequence Data , Mucin 5AC , Mucins/chemistry , Nuclear Magnetic Resonance, Biomolecular , Oligosaccharides/chemistry , Oligosaccharides/metabolism , Polymerase Chain Reaction , Sialic Acids/metabolism , Tumor Cells, Cultured
13.
Glycoconj J ; 15(1): 19-27, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9530953

ABSTRACT

In many cases of human cancer, the appearance of hypersialylated glycan structures is related to a precise stage of the disease; this may depend on altered regulation of one or more sialyltransferases genes. Since several distinct sialyltransferase enzymes arising from different unique genes transfer sialic acid residues in the same linkage onto the same acceptor, it is impossible to precisely determine which enzyme is involved in the observed phenotype based on enzymatic assays. We have developed a very sensitive and highly reproducible multiplex reverse transcriptase-polymerase chain reaction technique in order to monitor the expression of four human sialyltransferases genes ST6Gal I, ST3Gal I, ST3Gal III and ST3Gal IV in small cell samples. Multiplex PCR amplification using specific primers for each sialyltransferase and detection of amplification products by polyacrylamide gel electrophoresis is a method that is fast and easy to handle and has proven to be useful for establishing sialyltransferase patterns of expression in breast immortalized cell line HBL100 as well as in breast cancer cell lines MCF-7/6, MCF-7/AZ and MDA.


Subject(s)
Breast Neoplasms/enzymology , Polymerase Chain Reaction/methods , Sialyltransferases/metabolism , DNA Primers , Female , Humans , RNA, Messenger/genetics , RNA, Neoplasm/genetics , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...